Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”

Recently, we read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Yong-Bo, Cai, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157621/
https://www.ncbi.nlm.nih.gov/pubmed/35721889
http://dx.doi.org/10.3748/wjg.v28.i20.2248
_version_ 1784718673297014784
author Kang, Yong-Bo
Cai, Yue
author_facet Kang, Yong-Bo
Cai, Yue
author_sort Kang, Yong-Bo
collection PubMed
description Recently, we read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of this article, several valuable research directions are proposed to enhance the therapeutic effect of immune checkpoint inhibitors on advanced hepatocellular carcinoma.
format Online
Article
Text
id pubmed-9157621
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-91576212022-06-17 Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” Kang, Yong-Bo Cai, Yue World J Gastroenterol Letter to the Editor Recently, we read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of this article, several valuable research directions are proposed to enhance the therapeutic effect of immune checkpoint inhibitors on advanced hepatocellular carcinoma. Baishideng Publishing Group Inc 2022-05-28 2022-05-28 /pmc/articles/PMC9157621/ /pubmed/35721889 http://dx.doi.org/10.3748/wjg.v28.i20.2248 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Letter to the Editor
Kang, Yong-Bo
Cai, Yue
Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
title Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
title_full Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
title_fullStr Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
title_full_unstemmed Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
title_short Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
title_sort future prospect of “gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157621/
https://www.ncbi.nlm.nih.gov/pubmed/35721889
http://dx.doi.org/10.3748/wjg.v28.i20.2248
work_keys_str_mv AT kangyongbo futureprospectofgutmicrobiomecompositioncanpredicttheresponsetonivolumabinadvancedhepatocellularcarcinomapatients
AT caiyue futureprospectofgutmicrobiomecompositioncanpredicttheresponsetonivolumabinadvancedhepatocellularcarcinomapatients

Ejemplares similares